📋 Tender Overview
The DAK-Gesundheit intends to conclude non-exclusive discount agreements for pharmaceuticals under the relevant legal provisions. This involves a formal procurement process for the active ingredient Dapagliflozin, ATC A10BK01, with interested pharmaceutical companies. The contracts will be effective from October 1, 2026, to September 30, 2028, and will allow for the participation of all interested pharmaceutical companies under the same conditions throughout the contract duration. Dapagliflozin, ATC A10BK01
